Gene · 3020
H3-3A: H3.3 histone A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. H3-3A: H3.3 histone A. Genes, record 3020. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3020
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P84243 | Histone H3.3 | 136 | 103 | Ensembl, GeneID, HGNC |
Source UniProt
Patents136
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026506083 A | 2026-02-20 | 395 | P84243 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 48632 | P84243 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 48634 | P84243 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 48635 | P84243 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 48636 | P84243 | Espacenet |
| EP 4665855 A1 | 2025-12-24 | 395 | P84243 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1518 | P84243 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 38940 | P84243 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8114 | P84243 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1132 | P84243 | Espacenet |
1 to 10 of 136
See all 136 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,256
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | H3-3A papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 40 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 30 | 2025 |
| P01CA096832 | NORMAL & NEOPLASTIC GROWTH IN THE BRAIN | 23 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 21 | 2025 |
| P50CA097257 | Brain Tumor SPORE Grant | 16 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 15 | 2025 |
| R01NS076991 | Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and Leukodystrophies | 11 | 2025 |
| T32CA009676 | Training Program in Tumor Microenvironment | 9 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 8 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 6 | 2025 |
1 to 10 of 1,256Source NIH's project files
See all 1,256 nih grantsPapers2,385
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploring Molecular Pathways in Metastasis of Breast Cancer Cells to the Brain: Insights from Gene Expression Analysis and Cellular Origins. | J Microsc Ultrastruct | 2026 | 42824931 | PubTator, text mining | PubMed |
| H3F3B gene mutation in chondroblastomas: a multicenter study. | Acta Orthop Traumatol Turc | 2026 | 42813348 | PubTator, text mining | PubMed |
| Clinicopathological characteristics of giant cell tumor of bone and identification of a novel H3F3A p.V36_K37insL mutation. | Pathol Res Pract | 2026 | 42743822 | PubTator, text mining | PubMed |
| Exon-skipping antisense oligonucleotides for H3.3K27M-altered diffuse midline glioma therapy. | Mol Ther Nucleic Acids | 2026 | 42656813 | PubTator, text mining | PubMed |
| Sepsis-Induced Exosomal Transfer of MAFB mRNA Reprograms Hepatocytes via a miR-155-Jarid2-H3F3A Epigenetic Cascade. | Cells | 2026 | 42645209 | PubTator, text mining | PubMed |
| Xanthogranulomatous epithelial tumour of the calcaneus in a 32-year-old female: a rare entity. | Skeletal Radiol | 2026 | 42552430 | PubTator, text mining | PubMed |
| Clinical, surgical, and molecular characteristics and outcomes of adult patients with diffuse midline glioma, H3 K27-altered, treated with surgical resection. | J Neurooncol | 2026 | 42390632 | PubTator, text mining | PubMed |
| Incidence of malignant transformation in giant cell tumor of bone following denosumab therapy: a systematic review and meta-analysis. | J Bone Oncol | 2026 | 42382831 | PubTator, text mining | PubMed |
| The clinical and molecular landscape of thalamic glioma. | Neuro Oncol | 2026 | 42377275 | PubTator, text mining | PubMed |
| Needle-track metastasis in diffuse intrinsic pontine glioma: Need for a standardized surgical strategy? | Neurooncol Adv | 2026 | 42368381 | PubTator, text mining | PubMed |
1 to 10 of 2,385
See all 2,385 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3020
GET https://conductscience.org/api/genes/v1/3020/patents?page=2